Akebia Therapeutics (AKBA) Receivables (2013 - 2026)
Akebia Therapeutics (AKBA) recorded Receivables of $58.88 million in Q2 2026, down 57.4% from $138.21 million a year earlier and down 8.3% from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Receivables (2013 - 2026) Analysis & Trends
At the end of FY2025, Akebia Therapeutics reported Receivables of $49.62 million, up 36.4% from FY2024.
- Annual Receivables has a five-year compound annual growth rate of 9.4% (FY2020 to FY2025).
- Across earlier years, Receivables came in at $36.38 million in FY2024 (-14.7%), $42.62 million in FY2023 (-0.8%), $42.97 million in FY2022 (-42.7%) and $74.98 million in FY2021 (+137.1%).
- Quarterly Receivables has ranged from $19.15 million in Q1 2023 to $148.18 million in Q2 2022 over the past five years.
- On a year-over-year basis, Receivables rose in six of the last eight quarters, with growth averaging 71.2%.
- Peak year-over-year performance for Receivables in the last five years was growth of 337.5% in Q2 2025, against a decline of 86.4% in Q2 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $64.2 million (Q1 2026), $49.62 million (Q4 2025) and $69.28 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 25.23 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 18.99 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 13.51 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 12.74 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 16.16 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 10.35 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 5.01 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 14.19 Bn |
| 10 | Akebia Therapeutics | 149.86 Mn | -512.48 Mn | 30.54 Mn | 41.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 41.87 Mn |
| Jun 30, 2026 | 58.88 Mn |
| Mar 31, 2026 | 64.20 Mn |
| Dec 31, 2025 | 49.62 Mn |
| Sep 30, 2025 | 69.28 Mn |
| Jun 30, 2025 | 138.21 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Dec 31, 2024 | 36.38 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 31.59 Mn |
| Mar 31, 2024 | 29.31 Mn |
| Dec 31, 2023 | 42.62 Mn |
| Sep 30, 2023 | 23.07 Mn |
| Jun 30, 2023 | 20.10 Mn |
| Mar 31, 2023 | 19.15 Mn |
| Dec 31, 2022 | 42.97 Mn |
| Sep 30, 2022 | 30.75 Mn |
| Jun 30, 2022 | 148.18 Mn |
| Mar 31, 2022 | 93.64 Mn |
| Dec 31, 2021 | 74.98 Mn |
API Access
Akebia Therapeutics Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();